Results 11 to 20 of about 1,251,690 (298)

Constructing a Real-Time Prescription Drug Monitoring System [PDF]

open access: yesHealthcare Informatics Research, 2016
ObjectivesThe objective of this investigation was to demonstrate the possibility of the construction of a real-time prescription drug monitoring system (PDMOS) using data from the nationwide Drug Utilization Review (DUR) system in Korea.MethodsThe DUR ...
Young-Taek Park   +2 more
doaj   +1 more source

The Potential to Reduce Patient Co-Payment and the Public Payer Spending in Poland through an Optimised Implementation of the Generic Substitution: The Win-Win Scenario Suggested by the Real-World Big Data Analysis

open access: yesPharmaceutics, 2021
High medication costs are one of the major barriers to patient adherence. Medication affordability might be improved by generic substitution. The aim of this study was to assess the effectiveness of the implementation of generic substitution mechanisms ...
Przemysław Kardas   +7 more
doaj   +1 more source

The contribution of drug import to the cost of tuberculosis treatment: A cost analysis of longer, shorter, and short drug regimens for Karakalpakstan, Uzbekistan.

open access: yesPLOS Global Public Health, 2022
Tuberculosis (TB) programs depend on a continuous supply of large amounts of high-quality TB drugs. When TB programs procure TB drugs from international suppliers, such as the Global Drug Facility, they can incur import costs for international transport,
Stefan Kohler   +3 more
doaj   +2 more sources

Willingness to pay for treatment with highly active antiretroviral (HAART) drugs: a rural case study in Cameroon

open access: yesSAHARA-J, 2004
This paper reports on the willingness of HIV/AIDS patients to pay for the most affordable triple therapy combination of antiretrovirals in a local setting in Cameroon.
Kenneth Ngwambokong Muko   +5 more
doaj   +1 more source

Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]

open access: yes, 2010
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika   +10 more
core   +1 more source

Value‐based pricing: Toward achieving a balance between individual and population gains in health benefits

open access: yesCancer Medicine, 2020
Objectives Value‐based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value‐based pricing to reference cost‐effectiveness thresholds (λ)
Ambica Parmar   +3 more
doaj   +1 more source

Antiparasitic Drugs in the United States—Two Roads to High Prices

open access: yesFrontiers in Sociology, 2020
High prescription drug prices contribute significantly to healthcare spending in the United States and compromise patients' access to quality medical care.
Arman A. Shahriar   +2 more
doaj   +1 more source

Direct healthcare costs and their relationships with age at start of drug use and current pattern of use: a cross-sectional study

open access: yesSão Paulo Medical Journal, 2021
BACKGROUND: It is well known that early start of drug use can lead users to psychosocial problems in adulthood, but its relationship with users’ direct healthcare costs has not been well established OBJECTIVES: To estimate the direct healthcare costs ...
Paula Becker, Denise Razzouk
doaj   +1 more source

Consórcio de medicamentos no Paraná: análise de cobertura e custos A drug consortium in Paraná: analysis of coverage and costs

open access: yesRevista de Administração Pública, 2007
A redução de custos na compra de medicamentos é preocupação constante dos administradores públicos. Este artigo analisa a cobertura e custos do Consórcio Paraná Saúde (CPS), constituído para aquisição de medicamentos para prefeituras do Paraná.
Alide Marina Biehl Ferraes   +1 more
doaj   +1 more source

Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications [PDF]

open access: yesJournal of Primary Health Care, 2022
IntroductionNew medicines for the management of type 2 diabetes became available internationally in 2005, yet only in 2018 did the first of these become available in New Zealand.
Caroline Stretton   +2 more
doaj  

Home - About - Disclaimer - Privacy